Upstream / Downstream

pathwayImage

Explore pathways related to this product.

Antibody Guarantee

CST Antibody Performance Guarantee

LEARN MORE  

To Purchase # 8915LC

8915LC 10 µg (With Carrier)
8915LF 10 µg (Carrier Free)

To get local purchase information on this product, click here

Questions?

Find answers on our FAQs page.

ANSWERS  

Visit PhosphoSitePlus®

PTM information and tools available.

LEARN MORE

Source / Purification

Recombinant human TGF-β1 (hTGF-β1) Ala279-Ser390 (Accession #P01137) was expressed in human 293 cells at Cell Signaling Technology.

Product Description

Purity:

>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hTGF-β1. Less than 1% migrates as monomer hTGF-β1 under non-reduced (-) conditions. All lots are greater than 98% pure.


Molecular Formula:

Recombinant hTGF-β1 contains no "tags" and the nonglycosylated protein has a calculated MW of 12,794. DTT-reduced protein migrates as a 13 kDa polypeptide and the non-reduced cystine-linked homodimer migrates as a 25 kDa protein. The expected amino-terminal ALDTN of recombinant hTGF-β1 was verified by amino acid sequencing.


Bioactivity:

The bioactivity of recombinant hTGF-β1 was determined by assessing inhibition of IL-4 induced HT-2 cell proliferation. The ED50 of each lot is between 0.04-0.20 ng/ml.


Endotoxin:

Less than 0.01 ng endotoxin/1 μg hTGF-β1.


Product Usage Information

Formulation:

With carrier: Lyophilized from a 0.22 μm filtered solution of 20 mM citrate, pH 3.0 containing 100 mM NaCl and 20 μg BSA per 1 μg hTGF-β1. Carrier free: Lyophilized from a 0.22 μm filtered solution of 20 mM citrate, pH 3.0 containing 100 mM NaCl.


Storage: Stable in lyophilized state at 4°C for 1 year after receipt. Sterile stock solutions reconstituted with carrier protein are stable at 4°C for 2 months and at -20°C for 6 months. Avoid repeated freeze-thaw cycles.Maintain sterility. Storage at -20°C should be in a manual defrost freezer.

TGF-β1 activities include proliferation, angiogenesis and promotion or inhibition of many immune events (1-3). TGF-β1 is produced by a number of cell types including regulatory T cells, fibroblasts, epithelial cells, and endothelial cells (3). TGF-β1 binds to TβRII homodimer, which then complexes with TβRI homodimer (1,4). The oligomeric receptor complex phosphorylates subsets of the SMAD proteins that then act to induce and repress a number of target genes (1,3,4). TGF-β1 binding can also activate the Erk2, p38, and JNK pathways via TAK1 (4). TGF-β1 appears to promote late stage progression and metastasis in some cancers (1,2).


1.  Siegel, P.M. and Massagué, J. (2003) Nat Rev Cancer 3, 807-21.

2.  Bierie, B. and Moses, H.L. (2006) Nat Rev Cancer 6, 506-20.

3.  Tian, M. and Schiemann, W.P. (2009) Future Oncol 5, 259-71.

4.  Moustakas, A. and Heldin, C.H. (2009) Development 136, 3699-714.


Entrez-Gene Id 7040
Swiss-Prot Acc. P01137


For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.